Copyright
©The Author(s) 2023.
World J Clin Oncol. Nov 24, 2023; 14(11): 504-517
Published online Nov 24, 2023. doi: 10.5306/wjco.v14.i11.504
Published online Nov 24, 2023. doi: 10.5306/wjco.v14.i11.504
Figure 1 Flow diagram for searching and filtering eligible studies included in the meta-analysis.
Figure 2 Forest plots of the five studies show a shorter overall survival and disease-free survival/progression-free survival/recurrence-free survival in early pancreatic patients with positive pre-treatment or post-treatment circulating tumor cells detection.
A: Overall survival; B: Disease-free survival/progression-free survival/recurrence-free survival. CI: Confidence interval.
Figure 3 Forest plot of the three studies that used the CellSearch system shows a decreased disease-free survival/progression-free survival/recurrence-free survival in early pancreatic patients that were positive pre-treatment or post-treatment for circulating tumor cells.
CI: Confidence interval.
Figure 4 Sensitivity analysis of the influence of each study on the pooled results for the overall survival and disease-free sur vival/progression-free survival/recurrence-free survival subgroups.
A: Overall survival; B: Disease-free survival/progression-free survival/recurrence-free survival.
Figure 5 Funnel plots were generated for the included studies to determine whether or not publication bias was found for both the overall survival and disease-free survival/progression-free survival/recurrence-free survival subgroups.
A: Overall survival; B: Disease-free survival/progression-free survival/recurrence-free survival.
Figure 6 Forest plots of the four studies show that the carbohydrate antigen 19-9 level in the venous blood of early-stage pancreatic cancer patients was not an independent predictor of a shorter time to recurrence.
CI: Confidence interval.
Figure 7 Forest plots of the three studies, that detected the carbohydrate antigen 19-9 level in the venous blood before surgery, show that it was not an independent predictor of a shorter time to recurrence for early-stage pancreatic cancer patients.
CI: Confidence interval.
- Citation: Zhang ZH, Bao YW, Zhao YJ, Wang JQ, Guo JT, Sun SY. Circulating tumor cells as potential prognostic biomarkers for early-stage pancreatic cancer: A systematic review and meta-analysis. World J Clin Oncol 2023; 14(11): 504-517
- URL: https://www.wjgnet.com/2218-4333/full/v14/i11/504.htm
- DOI: https://dx.doi.org/10.5306/wjco.v14.i11.504